NEW YORK, Feb. 21, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Synergy Pharmaceuticals Inc. ("Synergy") (NASDAQ:SGYP) between September 5, 2017 and November 14, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-d/synergy-pharmaceuticals-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the loan from CRG Partners III L.P. (“CRG Loan”) did not fund Synergy’s operations through 2019; (2) the Company could not access the second tranche of $100 million financing on or before February 28, 2018 without issuing dilutive equity; and (3) the Company could not access the third tranche of the CRG Loan if and when needed because terms were required to be met in order to access those tranches. On September 5, 2017, Synergy issued a press release announcing it had closed on a “non-dilutive” $300 million loan from CRG Partners III L.P., which would be available to Synergy “when needed” and fund the Company’s operations through 2019. On November 14, 2017, Synergy revealed that terms of the loan agreement, omitted from prior statements regarding the loan, prevented it from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash and, as such, the Company was conducting a secondary offering of its shares.
If you suffered a loss in Synergy you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 



